/
Neurology
Neuropathic Pain
24
Pipeline Programs↗
36
Active Trials↗
52
Companies Involved↗
Neuropathic Pain is an emerging landscape with 24 programs across 52 companies. The most active players are Haisco Pharmaceutical Group Co., Ltd., Shanghai Yidian Pharmaceutical Technology Development Co., Ltd., Nanjing Chia-tai Tianqing Pharmaceutical. 5 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 1
No programs
Phase 25
Phase 35
Approved
No programs
Analysis
Modality Breakdown
96%
Small molecule
22 of 23 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 23 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.
Analysis
Trial Status
266
clinical trials
Completed160 · 60%
Terminated38 · 14%
Unknown status25 · 9%
Recruiting19 · 7%
Not yet recruiting12 · 5%
Withdrawn6 · 2%
Other6 · 2%
Clinical Trials
Trial Activity
266 trials
Crisugabalin for Radiotherapy-Related Neuropathic Pain
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT06766916·172 enrolled
Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain
Recruiting·—·Phase 4·NCT07451431·78 enrolled
Page 1 of 18
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)